Exploiting the Circadian Clock for Improved Cancer Therapy: perspective from a cell biologist
- 1BioMedizinisches Zentrum, Ludwig-Maximilians, Universität München, Germany
- 2Max Planck Institute of Biochemistry, Germany
- 3Center for Integrated Protein Science, Technical University of Munich, Germany
- 4Munich Cluster of Systems Neurology, Germany
Despite immense advances in cancer research and the development of novel therapies in oncology over the past decades, cancer remains one of the leading causes of death worldwide. According to the World Health Organization’s (WHO) estimates of cancer incidence and mortality of all ages and both sexes presented for 2012, there were c.a. 1.8 million new cases and 1.6 million deaths of lung cancer alone. Therapeutic treatment options for many of these cancers are limiting, despite of intense research activities and many technological and biological innovations. Indeed, from a standpoint of pharmaceutical development, recent analysis on the development of novel oncologic drugs for breast, colorectal, and non-small cell lung cancer show very high attrition rates. Between 1979 and 2014 alone (Nixon et al. 2017), attrition rate for new cancer therapies has been high, above >80% for drug classes including cytotoxic chemotherapeutic reagents and cancer immunomodulators. According to this analysis, oncological drugs are more likely to fail in late stage clinical trials (transition from Phase II to III) compared to other drugs. The authors concluded that adjusting and refining the design of early stage clinical trials may aid in the successful selection of drugs in later and more expensive stages of drug development (Nixon et al. 2017).
An additional, important aspect – and possibly the real, ‘biological’ crux of the matter at hand – is that the variation between individual patients to drugs is quite distinct. This highlights the urgency and a need to understand the variables that exist between individuals in order to improve the current status of cancer treatment. Such knowledge could clearly benefit the testing and selection of potential drugs for further development and clinical testing. From this standpoint, the distinct genetic and epigenetic make-up of individuals contributes greatly to individual variation. Increasingly, we will therefore likely see basked trials in oncology, for example, where patients are stratified based on genetic/genomic markers, such as the absence of a particular tumor suppressor gene, for example, rather than the etiology of the tumor itself. Moreover, emerging evidence in chronobiology strongly supports the intertwining relationship between our cyclic environmental, behavioral, and physiological cues on the biochemical and genetic activity of our tissues and organs.
The question then is how we can exploit our fundamental knowledge of environmental and metabolic cycles to improve cancer treatment? While many factors come into play, this brief perspective focuses on how an appreciation for circadian biology might improve on the clinical use of global care standards in cancer chemotherapy.
Laying the foundation for cancer chronotherapy
Over half a century ago, Dr. Mauricio Garcia-Sainz and Dr. Franz Halberg identified, through computational analyses, a 24-hour mitotic rhythmicity in human mammary but not squamous and basal cell cancer biopsy samples obtained before or after radiotherapy (Garcia-Sainz & Halberg 1966). They were able to distinguish the variance as rhythmicity <20 hours and observed a population reduction of such ultradian rhythmicity in samples obtained after radiotherapy. This discovery established chronopathology and opened up the conceptual possibility for the development of chrono-modulated therapies. However, the potential of this information did not fully blossom until the uncovering of the molecular clock in the 1990’s. Since then, Prof. Francis Albert Lévi, a clinician and scientist, his team, as well as others in the field have been actively researching and promoting the concept of targeting the circadian clock to improve current cancer treatments* (see a short interview with Prof. Lévi on page XX of this perspective). However, to date, cancer chronotherapy faces numerous challenges, which we will discuss in this article. In the following sections, we will provide a simplified summary of the circadian clock, how circadian regulatory network extends into chemotherapeutics, and summarize up-to-date implications of chronobiology in cancer therapy.
Life evolved in sync with the environment
Due to the Earth’s rotation, virtually all life has adapted and evolved an approximately 24-hour biological rhythmicity in order to anticipate periodic changes in our environment, such as light, temperature and food availability. This behavioral and physiological rhythmicity driven by natural sunlight is termed the circadian clock (circa diem). One tenable theory is that organisms evolved to store and utilize energy in synchrony with its environments. Thus, most fundamental biological processes such as cell metabolism and growth are thought to follow a daily circa 24-hour oscillation (for a review, see (Takahashi 2016)). However, a recent metabolomic analysis has elegantly demonstrated the existence of other (non-24-hour) rhythmicity and periodicity as well (Krishnaiah et al. 2017). Overall, cellular processes are thus greatly subjected to cyclic environmental cues, responses and behaviors.
Light entrains the central clock
In animals, the eye possesses the ability to sense light. Upon exposure to light, complex signals are sent through the retinohypothalamic tract and subsequently processed in the suprachiasmatic nucleus (SCN). In the SCN, a relatively small population of specialized cells regulates the synthesis of the hormone melatonin by the pineal gland. The result of fluctuating melatonin levels, in turn, triggers the ‘resetting’ of peripheral clocks, such as the liver and kidneys. These seemingly simple neurochemical and hormonal processes drive the most overt biological rhythmicity, the sleep-wake cycle, and is regarded as the central clock (for a review, see (Korf & Gall 2013)). However, the molecular mechanism of how melatonin and likely other hormones synchronize peripheral tissues remains unclear.
Nutrients regulate peripheral clocks
While natural cyclic exposure to light remains the key driver of our biological clocks, nutrients have emerged as another key factor in the synchrony of peripheral clocks. Liver, regarded as the metabolic hub, has been extensively characterized as a circadian organ (Koike et al. 2012). Transcriptomic and proteomic analyses on mice liver demonstrate the diurnal transcriptional and post-translational regulation of discrete cellular processes, which range from glucose and fatty acid metabolism to the cell-cycle and autophagy (Robles et al. 2016; Wang et al. 2018). In agreement, several clinical studies have reported circadian rhythmicity in glucose, lipid and energy metabolism, such as insulin sensitivity and secretion, cholesterol synthesis and fat oxidation (Poggiogalle et al. 2018). These findings further strengthen the concept of multiple cellular processes being under the direct and indirect influence of our environment, nutrition, metabolism and behavior.
The molecular clock drives transcriptional rhythmicity
At the cellular level, neurochemical and hormonal cues induced by light and nutrients prompt the resetting of the molecular clock. However, the molecular clock is governed by several interlocking transcription and translation feedback loops (TTFLs), which proceeds for a long time even in the absence of external cues. A recent, groundbreaking circadian transcriptomics study in the olive baboon (Papio anubis) revealed over 80% of protein-coding genes displayed a daily oscillation pattern in more than 60 examined tissues (Mure et al. 2018). The majority of cycling genes were mainly ubiquitously expressed genes, which are often involved in fundamental cellular processes, such as circadian rhythmicity, DNA replication, DNA repair, amino-sugar metabolism and oxidative phosphorylation (Mure et al. 2018).
To conclude, the biochemical and genetic response of a metazoan organism is influenced not only by our predetermined genetic and epigenetic make-up; but also by a plethora of ever-changing external stimuli, including light and nutrients. Thus, in addition to well-studied genetic (Kandoth et al. 2013) and metabolic alterations (DeNicola & Cantley 2015) in cancer, we must now take into account both ‘clock alterations’ and clock regulatory genetic and metabolic networks. Only in combination, will we potentially succeed in profiling cancer subtypes and strategizing treatments. In the following section, we will present our case on cancer chronotherapy and up-to-date findings on the relationship between the clock, cancer, and chemotherapeutics.
Circadian clock function influences cancer and vice-versa
Several recent findings indicate that there is a correlation between the circadian clock and the etiology of cancer. One study reported that clock genes in human tumor samples have altered gene expression profiles in comparison to normal, adjacent tissues (Ye et al. 2018). To no surprise, they also found a correlation between clock gene expression and anti-cancer drug sensitivity in cancer cell lines (Ye et al. 2018). To support this, a number of experimental and clinical studies have reported a negative correlation between clock disruption during and/or after treatment with survival rate in cancer animal models and patients (Sephton et al. 2013; Lévi et al. 2014; Papagiannakopoulos et al. 2016). These findings indicate a dysfunctional or functional clock may serve as an indicator for the outcome of cancer progression and treatment response. However, circadian modulated anti-cancer drug response and the potential effect of our environment and behavior on cancer development lack well-defined molecular insights necessary to comprehend and exploit the clock for common cancer treatments. In the following paragraphs, we summarize state-of-the-art findings in explaining how the circadian clock may improve the current status of cancer chemotherapy.
Cytotoxic chemotherapy as the global standard of care
There are various approaches targeted at treating cancer. Notably, in recent years, immunotherapeutic approaches have shown great promise and interest in the research and clinical community. Nevertheless, conventional chemotherapy, regardless whether administered as induction, combined, consolidation or through other therapeutic strategies, remains one of the most broadly used and affordable treatments following the surgical resection of tumor tissue. Despite current knowledge on how, for example, platinum-based and similar chemotherapeutic drugs function, debilitating adverse effects resulting from severe damage to normal and healthy tissues limits the dosing of drugs and treatment duration (Tacar et al. 2012; Dasari & Bernard Tchounwou 2014). Using chemotherapeutic drugs at suboptimal doses and treatment duration, in turn, provides space for the cancer to develop drug resistance. Cancer therapy using chemotherapeutic agents thus persistently faces the major challenge of relapse. In the following, we summarize how the clock regulates the DNA damage repair machinery targeted by cytotoxic chemotherapeutical drugs, drug metabolism and potentially drug resistance in cancer.
The molecular clock regulates the DNA repair machinery
Conventional chemotherapy targets cells with enhanced proliferation rates and/or an impaired DNA repair machinery to achieve elimination of cancerous cells (Corrie 2008). The circadian clock regulates these key hallmarks of cancer of which includes cell proliferation, metabolism and genome stability (for extensive reviews, see (Masri et al. 2013; Panda 2016; Sancar et al. 2010)). For example, cisplatin, a widely used and well-established chemotherapeutic drug in the treatment of numerous human cancers, exerts its function by crosslinking purine bases on DNA, causing bulky lesions. These bulky lesions interfere with DNA replication and overwhelm the DNA repair machinery, which generally results in cell death (for a review, see (Dasari & Bernard Tchounwou 2014)). These bulky DNA adducts are typically sensed and resolved by the nucleotide excision repair (NER) pathway. The activity of one particular key DNA repair protein, xeroderma pigmentosum A (XPA), was shown to be under direct circadian control in vivo (Kang et al. 2009; Kang et al. 2010). This knowledge strengthens the notion of timed drug (such as cisplatin) administration in accordance to the circadian ‘trough’ of the targeted cell process (in this case, NER repair machinery) to increase drug efficiency.
Drug resistance emerges out of cell mechanisms under circadian control
Cancer is a highly heterogeneous disease, rendering it a challenge to target and treat, as the genome rapidly evolves and resistance mechanisms arise albeit the simplicity of ‘timely’ targeting. There are several proposed mechanisms of resistance to chemotherapy. Beside suboptimal drug dosage and treatment duration, this includes changes in the cellular uptake and efflux of the chemotherapeutic agent, increased drug metabolism and elimination, as well as enhanced DNA repair machineries, mechanisms, which suppress tumor cell death (Mansoori et al. 2017). These resistance mechanisms emerge from processes that are controlled by the circadian clock (Dallmann et al. 2014; Dallmann et al. 2016; Sancar et al. 2010). Thus far, clinical studies have shown that several adverse effects experienced by cancer patients taking cisplatin-based chemotherapy decreases when cisplatin is applied in a chrono-modulated context (Zhang et al. 2017; Li et al. 2015). The results and outcomes of these studies indicate that the proper timing of drug administration reduces cisplatin-induced adverse effects in patients. Chronotherapy may thus potentially enable substantial increases in the maximally tolerated dose. This raises the possibility that more effective toxicity to the tumor cells could be achieved, providing potentially a higher selectivity relative to the toxic effect of chemotherapy on normal cells.
In sum, the clock regulates the fundamental cell processes, which are often the targeted machinery of cytotoxic anti-cancer drugs. The clock also modulates the absorption, metabolism and elimination of these drugs. In combination, chrono-modulated drug administration provides the potential to optimize the dosage of drugs and duration of treatments to efficiently eliminate highly proliferative cancerous cells while reducing limiting adverse effects to circumvent drug resistance. The potential for chronotherapy thus arises out of the physiological link between the cytotoxic cancer agents and molecular processes that respond to these agents on an organismic and cellular level.
Current challenges and future directions in cancer chronotherapy
Several studies report clear changes in the effectiveness of cancer chronotherapy. However, significant interpatient variability persistently poses a major challenge for cancer chronotherapy to gain statistical power (Ballesta et al. 2017). Giacchetti and colleagues conducted a comparative meta-analysis on conventional and chrono-modulated chemotherapeutic treatments in 842 patients with metastatic colorectal cancer, who participated in one of three international randomized trials (Giacchetti et al. 2012). They found improved tumor response rate and overall survival, as compared to conventional chemotherapy in male patients by +3.3 months. Unexpectedly, the overall survival of female patients decreased by 1.8 months (Giacchetti et al. 2012). One pilot study involving 55 healthy people and 12 cancer patients found significant sex- and age-related variations in the coordination of individual circadian clocks as well (Komarzynski et al. 2018). These critical findings underscore the relevance of sex and age for cancer chronotherapy and require further investigations on their respective impacts for the scheduling of chronotherapy. Such variations likely stem from and result in the challenges listed below.
There are at least three challenges faced by cancer chronotherapy. These include:
1) there is insufficient mechanistic insight at the level of basic research of how cancer and chemotherapeutic drugs affect the molecular clock and vice versa. This hampers the design of appropriate chrono-modulated clinical trials.
In the last decade, tremendous effort has been put into deciphering the structure, function and regulatory network of the molecular clock and its core components. While the field is rapidly gaining new insights on these fundamental biological questions, we have yet directly addressed the impact of the clock and metabolic environment on cytotoxic drug sensitivity in a systematic manner. We suggest that the field requires a systematic high-throughput cell (organelle)-based screening capability on the circadian-dependent effects of chemotherapeutic cytotoxicity in both model cancer and primary cell lines. This would help confer novel mechanistic information. Ultimately, such information could provide valuable data to generate unique combinatorial (cancer, drug, and clock) profiles which may serve as guidelines clinical trial designs.,
2) In clinical research, large variations among patients’ clocks can alter the statistical power of trials comparing
chronotherapy to conventional treatment in patients with varying chronotypes (circadian clock).
Cancer profiling is under constant refinement from tumor localization, cell morphology, cell surface biomarkers to genetic and epigenetic aberrations. We now must also acknowledge that the variation extends to our biological clocks. The design of chrono-modulated chemotherapy may benefit immensely from compulsory documentation of patient routines including sleep/wake cycles, activity, metabolic profile, and drug administration in all related drug trials. While this is of course a great challenge in terms of data gathering and analysis, the European Medicines Agency and its nearing auditable release of the EU IT systems (in March, 2019) with uniformed regulations and absolute transparency will aid us in moving towards an improved era of personalized and precise medicine tailored to individual chronotypes.
3) Pharmaceutical companies should be incentivized to invest in (re-)examining the time-dependent efficacy and toxicity of chemotherapeutic drugs, or to design clock-based drugs.
As suggested earlier (Nixon et al. 2017), the adjustment and refinement of early stage clinical trial design could permit a higher success rate in anti-cancer drug development. To put this into perspective, it costs on average a striking $2.6 billion USD to develop a drug (DiMasi et al. 2016). Considering the attrition rate of 80%, chronotherapeutic approaches could lead to the development of effective new anti-cancer drugs or improved dosing regimens. Pharmaceutical companies should take into account the effect of the clock and recognize the potential in re-examining drugs to increase not only the therapeutic value of approved drugs, but also re-evaluate new chemical entities.
In conclusion, these interlinking challenges require collaborative efforts between basic science and medicine, clinicians, regulatory authorities and pharmaceutical companies in order to obtain mechanistic insights and clinical statistics that would help shed light on how a given cancer affects the clock and vice versa, how a given oncotherapy affects the clock and what other factors, such as our lifestyle and environment (personal chronotypes), can affect the clock and treatment responses. The landscape of chronotherapy is gradually maturing, as progress in in silico pharmacology (Ekins et al. 2007), clinical big data (Mayo et al. 2017; Singh et al. 2018), in vitro pharmacology and mathematical modeling (Dulong et al. 2015) help to expand our knowledge of the molecular clock and its relevance to human disease, consistent with the important trend toward personalized medicine. Here, we have analyzed and explored the case for chronotherapy as an option to improve the effectiveness of existing and future cancer therapies. A better appreciation and analysis of the potential for chronotherapy could benefit many cancer patients worldwide, so we should give this fundamental underlying biological phenomenon the chance that it deserves.
Keywords: Chronotherapeutic, circdian rhythm, chemotherapy, Cancer, Precision (stratified) medicine
Received: 18 Mar 2019;
Accepted: 04 Nov 2019.
Copyright: © 2019 Kuo and Ladurner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ms. Tia Tyrsett Kuo, BioMedizinisches Zentrum, Ludwig-Maximilians, Universität München, Munich, Germany, firstname.lastname@example.org